PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Michiya Matsusaki Osaka University to Speak at Tissue Models Conference on May 6-7 in Berlin - Michiya Matsusaki, Assistant Professor at Osaka University, will speak about “Construction of Vascularized 3D Human Tissue Models and Their Applications for Drug Screening” at the Tissue Models & Drug Screening Conference, taking place May 6-7, 2014
Michiya Matsusaki Osaka University to Speak at Tissue Models Conference on May 6-7 in Berlin

 

NewswireToday - /newswire/ - Monrovia, CA, United States, 2014/01/27 - Michiya Matsusaki, Assistant Professor at Osaka University, will speak about “Construction of Vascularized 3D Human Tissue Models and Their Applications for Drug Screening” at the Tissue Models & Drug Screening Conference, taking place May 6-7, 2014.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Michiya Matsusaki, Assistant Professor at Osaka University, will speak about “Construction of Vascularized 3D Human Tissue Models and Their Applications for Drug Screening” at the Tissue Models & Drug Screening Conference, taking place May 6-7, 2014 in Berlin.

Developing artificial three-dimensional (3D) human tissues containing blood and lymph capillary networks is one of the key challenges in tissue engineering, and modulating 3D cell-cell interaction inside the 3D artificial tissues is a particularly significant issue. Dr. Matsusaki will share how his lab developed simple and unique bottom-up approaches using nanometer-sized, layer-by-layer films consisting of fibronectin and gelatin (FN-G) as a nanometer-sized extracellular matrix. The FN-G nanofilms were prepared directly on the cell surface and acted as a stable adhesive surface for interaction with the neighbor cells. This approach easily provided approximately 10 to 20 layered tissues and fully vascularized tissues, after only one day of incubation, and a sandwich culture of the endothelial cells obtained a width of over one centimeter.

When the lab used lymph endothelial cells together with blood endothelial cells, the individual capillary networks of blood and lymph capillaries were successfully obtained. Moreover, perfusable vascular networks, which have an opening pore at the surfaces, were constructed by controlling the cell location. Various molecules, nanoparticles, and blood cells were able to be injected into both the blood and lymph capillaries. These vascularized 3D tissues will be useful as an artificial human tissue model for tissue engineering and pharmaceutical applications.

Michiya Matsusaki received his Ph.D. degree in 2003 under the direction of Prof. Mitsuru Akashi from Kagoshima University, Japan. In 2005, he joined the Department of Applied Chemistry in the Graduate School of Engineering at Osaka University as a designated assistant professor. Since 2006, he has been an assistant professor of the department, where his research focus is on functional polymers and biomaterials for biomedical and tissue engineering applications.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: GTCbio - Biopharmaceutical Conference

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Michiya Matsusaki Osaka University to Speak at Tissue Models Conference on May 6-7 in Berlin

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

|
Publisher Contact: GTCbio.com 
626-256-6405 kristen.starkey[.]gtcbio.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any GTCbio - Biopharmaceutical Conference securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From GTCbio - Biopharmaceutical Conference / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

U.S. FDA Approves New Indication for Ipsen’s Somatuline® Depot (lanreotide) Injection for the Treatment of Carcinoid Syndrome
Genentech Provides Update on First Lampalizumab Phase III Study for Geographic Atrophy, an Advanced Form of Age-Related Macular Degeneration
mProve Health and Greenphire Partner to Deliver a First-of-its-Kind Patient Engagement Solution
FDA Approves Genentech’s Actemra (Tocilizumab) for the Treatment of CAR T Cell-Induced Cytokine Release Syndrome
Greenphire Named to Inc. 5000 for Fifth Consecutive Year
Five Community Health Centers Honored for Innovative Approaches to Medication Therapy Management
FDA Grants Priority Review for Genentech’s Gazyva in Previously Untreated Follicular Lymphoma
ProSci Incorporates Flow Cytometry Screening to Custom Monoclonal Antibody Service
FDA Grants Priority Review to Genentech's Emicizumab for Hemophilia A with Inhibitors
BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow Ltd

Visit  JobsWare.com





 
  ©2017 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)